Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/13/24
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 05/22/23
End: 12/31/25
Due: 12/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) | NCT06394830 | Vaneltix Pharma, Inc. | user2@example.com | None | 2024-12-13 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS | NCT05737121 | Vaneltix Pharma, Inc. | user2@example.com | None | 2023-05-22 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |